Search results for "Biomarkers"

showing 10 items of 2658 documents

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

2021

Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of pro-atherogenic transcription factors that activate the "inflammasome". In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called "advanced glycosylation end products" (AGE). Laboratory information provided by the level of bio…

0301 basic medicineBlood GlucoseNovel biomarkersDisease030204 cardiovascular system & hematologyBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGlycationRisk FactorsDiabetes mellitusType 2 diabetes mellitusMedicineHumansEndothelial dysfunctionRisk factorMolecular BiologyGlycemicInflammationGlycationbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCardiovascular risk030104 developmental biologychemistryDiabetes Mellitus Type 2Cardiovascular DiseasesOxidative stressMolecular MedicineAdvanced glycation end-productbusinessReactive Oxygen SpeciesBiomarkers
researchProduct

Emerging insights on the biological impact of extracellular vesicle-associated ncRNAs in multiple Myeloma

2020

Increasing evidence indicates that extracellular vesicles (EVs) released from both tumor cells and the cells of the bone marrow microenvironment contribute to the pathobiology of multiple myeloma (MM). Recent studies on the mechanisms by which EVs exert their biological activity have indicated that the non-coding RNA (ncRNA) cargo is key in mediating their effect on MM development and progression. In this review, we will first discuss the role of EV-associated ncRNAs in different aspects of MM pathobiology, including proliferation, angiogenesis, bone disease development, and drug resistance. Finally, since ncRNAs carried by MM vesicles have also emerged as a promising tool for early diagnos…

0301 basic medicineBone diseaselcsh:QH426-470AngiogenesisReviewBiologyBiochemistry03 medical and health sciences0302 clinical medicineMultiple myelomaGeneticsmedicineNon-coding RNAMolecular BiologyMultiple myelomaRNAbiomarkersBiological activityExtracellular vesicleBiomarkermedicine.diseaseNon-coding RNAlcsh:Genetics030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisDrug resistanceCancer researchBone marrowprogressionExtracellular vesicleextracellular vesicles
researchProduct

The potential of cystatin C as a predictive biomarker in breast cancer

2020

Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients.This review analyzes the results of emerging studies underpinning a potential clinical role of Cyst C, as additional marker in BCa.Cyst C e…

0301 basic medicineBreast NeoplasmsMetastasiCysteine proteinaseMetastasisCathepsin03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerBiomarkers Tumorproteinase inhibitorMedicineAnimalsHumansPharmacology (medical)Cystatin Cskin and connective tissue diseasesPredictive biomarkerNeoplasm StagingCathepsinbiologybusiness.industryTumor progressionjCystatin C CystatinCysteine proteinasesmedicine.diseasePrognosis030104 developmental biologyOncologyCystatin CTumor progression030220 oncology & carcinogenesistumor markerCancer researchbiology.proteinDisease ProgressionFemalebusiness
researchProduct

A headlight on liquid biopsies: a challenging tool for breast cancer management

2016

Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a bas…

0301 basic medicineCA15-3OncologyCancer Researchmedicine.medical_specialtyPathologyBiopsyBreast NeoplasmsMetastasis03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerCirculating tumor cellInternal medicineBiopsyBiomarkers TumormedicineCarcinomaHumansPTENNeoplasm MetastasisLiquid biopsyBreast cancer; Circulating tumor cells; Circulating tumor DNA; CTCs; ctDNA; Liquid biopsy; Cancer ResearchCirculating tumor DNALiquid biopsybiologymedicine.diagnostic_testbusiness.industryCirculating tumor cellctDNADNA NeoplasmGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseCTC030104 developmental biology030220 oncology & carcinogenesisbiology.proteinFemalebusinessTumor Biology
researchProduct

Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.

2015

Background: Multiple sclerosis is a chronic inflammatory central nervous system disease diagnosed by clinical presentation and characteristic magnetic resonance imaging findings. The role of cerebrospinal fluid (CSF) analysis has been emphasized in particular in the context of differential diagnosis in patients with a first episode suggestive of multiple sclerosis. Objective: We investigated here the potential additional value of analysis of CSF cellularity by fluorescence activated cell sorting (FACS) in the setting of a routine diagnostic work-up in our inpatient clinic. Methods: CSF cells from back-up samples from patients with suspected chronic inflammatory central nervous system disord…

0301 basic medicineCD4-Positive T-LymphocytesMalePathologyTime FactorsLipopolysaccharide ReceptorsCell SeparationCD8-Positive T-LymphocytesMonocytes0302 clinical medicineCerebrospinal fluidCerebrospinal FluidClinically isolated syndromemedicine.diagnostic_testMiddle AgedFlow CytometryPrognosisMagnetic Resonance Imagingmedicine.anatomical_structurePhenotypeNeurologyDisease ProgressionFemaleAdultmedicine.medical_specialtyMultiple SclerosisAdolescentT cellImmunophenotypingCentral nervous system disease03 medical and health sciencesYoung AdultPredictive Value of TestsmedicineHumansB cellAgedbusiness.industryMonocyteMultiple sclerosisOligoclonal BandsMagnetic resonance imagingmedicine.diseaseAntigens CD20030104 developmental biologyImmunologyNeurology (clinical)business030217 neurology & neurosurgeryBiomarkersDemyelinating DiseasesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis.

2016

KANSL2 is an integral subunit of the nonspecific lethal (NSL) chromatin-modifying complex that contributes to epigenetic programs in embryonic stem cells. In this study, we report a role for KANSL2 in regulation of stemness in glioblastoma (GBM), which is characterized by heterogeneous tumor stem-like cells associated with therapy resistance and disease relapse. KANSL2 expression is upregulated in cancer cells, mainly at perivascular regions of tumors. RNAi-mediated silencing of KANSL2 in GBM cells impairs their tumorigenic capacity in mouse xenograft models. In clinical specimens, we found that expression levels of KANSL2 correlate with stemness markers in GBM stem-like cell populations. M…

0301 basic medicineCHROMATINMaleCancer ResearchCarcinogenesisCellCell SeparationMice SCIDmedicine.disease_causeMiceCANCER STEM CELLMice Inbred NODHistone AcetyltransferasesOligonucleotide Array Sequence AnalysisBrain NeoplasmsNuclear ProteinsMiddle AgedFlow CytometryImmunohistochemistryChromatinUp-Regulationmedicine.anatomical_structureOncologyGene Knockdown TechniquesNeoplastic Stem CellsHeterograftsFemaleCIENCIAS NATURALES Y EXACTASAdultKANSLOtras Ciencias BiológicasBlotting WesternGLIOBLASTOMABiologyReal-Time Polymerase Chain ReactionArticleCiencias Biológicas03 medical and health sciencesCancer stem cellmedicineBiomarkers TumorGene silencingAnimalsHumansEpigeneticsAgedEmbryonic stem cell030104 developmental biologyCancer cellImmunologyCancer researchCarcinogenesisGlioblastomaCancer research
researchProduct

Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance

2019

Cancer-derived extracellular vesicles (EVs) have been detected in the bloodstream and other biofluids of cancer patients. They carry various tumor-derived molecules such as mutated DNA and RNA fragments, oncoproteins as well as miRNA and protein signatures associated with various phenotypes. The molecular cargo of EVs partially reflects the intracellular status of their cellular origin, however various sorting mechanisms lead to the enrichment or depletion of EVs in specific nucleic acids, proteins or lipids. It is becoming increasingly clear that cancer-derived EVs act in a paracrine and systemic manner to promote cancer progression by transferring aggressive phenotypic traits and drug-res…

0301 basic medicineCancer ResearchBiologyExtracellular Vesicles03 medical and health sciencesParacrine signalling0302 clinical medicineNeoplasmsmicroRNABiomarkers TumormedicineHumansPharmacology (medical)Liquid biopsyPharmacologyTumor microenvironmentLiquid BiopsyCancermedicine.diseasePrecision medicineMicrovesicles030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellDisease ProgressionCancer researchDrug Resistance Updates
researchProduct

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

2018

AbstractPurpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score ≥4 and/or recurred after a median of 58 months and were considered endocrine resistant. Integration of the 47 most upregulated genes (log FC > 1, FDR < 0.03) in letrozole-resistant tumors with transcription-binding data showed significant overlap with 20 E2F4-regulated genes (P =…

0301 basic medicineCancer ResearchBreast NeoplasmsE2F4 Transcription FactorArticle03 medical and health sciences0302 clinical medicineText miningDownregulation and upregulationCell Line TumorBiomarkers TumormedicineHumansEndocrine systemProtein Kinase InhibitorsE2F4GeneAgedCell ProliferationAged 80 and overAromatase Inhibitorsbusiness.industryGene Expression ProfilingLetrozoleEndocrine therapyComputational BiologyMiddle AgedEMTREE drug terms: aromatase inhibitorcyclin dependent kinase 4cyclin dependent kinase 6cyclin dependent kinase inhibitorfulvestrantletrozolepaclitaxelpalbociclibtranscription factor E2F4estrogen receptorletrozoleprotein kinase inhibitortranscription factor E2F4transcriptometumor marker030104 developmental biologyReceptors EstrogenOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisLetrozoleMutationRetreatmentCancer researchFemaleTranscriptomebusinessmedicine.drug
researchProduct

The phospholipase DDHD1 as a new target in colorectal cancer therapy

2018

Background Our previous study demonstrates that Citrus-limon derived nanovesicles are able to decrease colon cancer cell viability, and that this effect is associated with the downregulation of the intracellular phospholipase DDHD domain-containing protein 1 (DDHD1). While few studies are currently available on the contribution of DDHD1 in neurological disorders, there is no information on its role in cancer. This study investigates the role of DDHD1 in colon cancer. Methods DDHD1 siRNAs and an overexpression vector were transfected into colorectal cancer and normal cells to downregulate or upregulate DDHD1 expression. In vitro and in vivo assays were performed to investigate the functional…

0301 basic medicineCancer ResearchColorectal cancerApoptosisMiceSettore BIO/13 - Biologia ApplicataGene Regulatory NetworksMolecular Targeted TherapyCitrus-limon nanovesicleTransfectionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthCitrus-limon nanovesicles; Colorectal cancer; Phospholipase DDHD1; Oncology; Cancer ResearchOncologyPhospholipasesCitrus-limon nanovesicles; Colorectal cancer; Phospholipase DDHD1; Animals; Antineoplastic Agents; Apoptosis; Cell Line Tumor; Cell Proliferation; Colorectal Neoplasms; Computational Biology; Disease Models Animal; Female; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Gene Silencing; Humans; MAP Kinase Signaling System; Mice; Phospholipases; Signal Transduction; Xenograft Model Antitumor Assays; Biomarkers Tumor; Molecular Targeted TherapyFemaleColorectal NeoplasmsSignal TransductionMAP Kinase Signaling SystemAntineoplastic Agentslcsh:RC254-282Citrus-limon nanovesicles03 medical and health sciencesDownregulation and upregulationIn vivoCell Line TumorBiomarkers TumormedicineAnimalsHumansGene silencingGene SilencingPhospholipase DDHD1Cell Proliferationbusiness.industryCell growthGene Expression ProfilingResearchComputational BiologyCancermedicine.diseaseXenograft Model Antitumor AssaysColorectal cancerDisease Models AnimalGene Ontology030104 developmental biologyApoptosisCancer researchbusiness
researchProduct